
Alume Biosciences: Pioneering nerve illumination technology for enhanced surgical precision.
Founded with a mission to enhance surgical precision, Alume Biosciences focuses on developing proprietary nerve illumination technology. This innovative technology aims to assist surgeons in identifying and preserving nerves during operations, thereby reducing the risk of nerve damage and associated complications such as incontinence and erectile dysfunction in prostate surgeries, and facial nerve damage in head and neck surgeries. The company is dedicated to making this technology widely available to improve patient outcomes globally.
Dr. Quyen Nguyen, a prominent surgeon-scientist, is a key figure affiliated with Alume Biosciences. The company has garnered attention for its groundbreaking approach to surgical care, attracting investors interested in advancing medical technology. Alume Biosciences' nerve illumination technology has the potential to significantly impact the field of surgery by reducing postoperative complications and improving the quality of life for patients worldwide.

Illuminare Biotechnologies
illuminarebio.com

Alamar Biosciences
alamarbio.com

Alumis
alumis.com

OnLume
onlume.com

Alucent Biomedical
alucentmedical.com

Avelas Biosciences

BioCircuit Technologies
biocircuit.com

Alveolus Bio
alveolusbio.com

Alcyone Lifesciences

Alterome Therapeutics
alterome.com

Allotrope Medical

Alpenglow Biosciences

Vergent Bioscience
vergentbio.com

Alkeus Pharmaceuticals
alkeus.com

Blaze Bioscience
Companies similar to Alume Biosciences include Illuminare Biotechnologies, Alamar Biosciences, Alumis and OnLume.
Alume Biosciences was founded in 2017.
Alume Biosciences' headquarters is located in San Diego, CA, US.
Alume Biosciences' most recent funding round was for $13M (USD) in January 2023.
As of Jan 10, 2023, Alume Biosciences has raised a total of $27.7M (USD).
Alume Biosciences has 12 employees as of Feb 5, 2024.